{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:08:43Z","timestamp":1791950923845,"version":"4.3.4"},"reference-count":10,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,30]]},"DOI":"10.1182\/blood.2022019246","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T15:32:22Z","timestamp":1680190342000},"page":"1505-1506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Is\u00a0BCL-xL\u00a0the Achilles' heel of AEL and AMKL?"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9711-9769","authenticated-orcid":false,"given":"Fiona C.","family":"Brown","sequence":"first","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research"},{"name":"2Monash University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research"},{"name":"2Monash University"},{"name":"3The University of Melbourne"},{"name":"4Peter MacCallum Cancer Centre"},{"name":"5Royal Melbourne Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2023033015313920300_","first-page":"1701","volume-title":"The WHO classification of haematolymphoid tumours","author":"Cree","year":"2022"},{"issue":"6","key":"2023033015313920300_","first-page":"6988","article-title":"Clinical diagnosis of adult patients with acute megakaryocytic leukemia","volume":"16","author":"Zhao","year":"2018","journal-title":"Oncol Lett"},{"issue":"2","key":"2023033015313920300_","doi-asserted-by":"crossref","first-page":"a034884","DOI":"10.1101\/cshperspect.a034884","article-title":"Acute megakaryocytic leukemia","volume":"10","author":"McNulty","year":"2020","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"10","key":"2023033015313920300_","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2009-09-243964","article-title":"Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification","volume":"115","author":"Hasserjian","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2023033015313920300_","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2023033015313920300_","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"2023033015313920300_","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"issue":"5","key":"2023033015313920300_","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in\u00a0patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023033015313920300_","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2023033015313920300_","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/13\/1505\/2040666\/blood_bld-2022-019246-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/13\/1505\/2040666\/blood_bld-2022-019246-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T11:49:34Z","timestamp":1680436174000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/13\/1505\/495015\/Is-BCL-xL-the-Achilles-heel-of-AEL-and-AMKL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":10,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,3,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022019246","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}